Akebia Therapeutics (AKBA) Stock: Buy, Sell, or Hold?
AKBA - Akebia Therapeutics, Inc.
$0.92
0.01 (1.64%)
â˛
5d:
-3.78%
30d:
+6.72%
90d:
-6.73%
WAIT
LOW Confidence
Analysis Updated: Sep 16, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When AKBA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: AKBA is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: AKBA is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: AKBA is currently trading at $0.92, which is considered fair relative to its 30-day fair value range of $0.87 to $0.96. From a valuation perspective, the stock is trading at a discount (Forward PE: -2.5) compared to its historical average (12.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AKBA is in a downtrend. The price is currently testing key support at $0.90. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 47/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $3.92 (+326.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AKBA is in a downtrend. The price is currently testing key support at $0.90. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 47/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $3.92 (+326.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.87 -
$0.96
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
Protect Your Profits
Holding AKBA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (47/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 326.7% below Wall St target ($3.92)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.87 -
$0.96
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.90
Resistance Level
$1.05
Current Trend
Downtrend
Technical data as of
Sep 16, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.55
Wall Street Target
$3.92
(+326.7%)
Revenue Growth (YoY)
-21.4%
Profit Margin
-13.5%
PE vs Historical
-2.6 vs 12.4
CHEAP
Share & Embed Analysis
Last updated: September 17, 2026 12:45 AM ET
Data refreshes hourly during market hours. Next update: 1:45 AM
Data refreshes hourly during market hours. Next update: 1:45 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AKBA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$211 | 48 HOLD |
|
BCRX
BioCryst PharmaceuticalsâĻ |
STRONG BUY
12 analysts |
$21 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 51 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 50 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 51 HOLD |
Advanced AKBA Option Strategies
Professional options setups generated by AI based on today's AKBA price and gamma walls.
